Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria. This adds to our broad geographic coverage, including a patent granted last year in China. BioAegis is pursuing worldwide patent filings for infectious disease.
December, 2014: Plasma Gelsolin Broad Infectious Disease Patents Granted in Europe, Canada, Hong Kong and Australia
- December 28, 2014